EGFR and non-small cell lung carcinoma: Recently, in order to investigate mechanisms leading to resistance to EGFR-targeted therapy, two NSCLC cell lines (HCC827 and HCC4006) have been used to derive in vitro models of acquired resistance to the EGFR TKI erlotinib [30].